1. Home
  2. CSTL vs GILT Comparison

CSTL vs GILT Comparison

Compare CSTL & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$35.08

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

N/A

Current Price

$7.36

Market Cap

599.3M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
GILT
Founded
2007
1987
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical Specialities
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
599.3M
IPO Year
2019
1997

Fundamental Metrics

Financial Performance
Metric
CSTL
GILT
Price
$35.08
$7.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
3
Target Price
★ $46.70
$19.20
AVG Volume (30 Days)
323.1K
★ 988.8K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $344,229,000.00
N/A
Revenue This Year
$8.68
$12.44
Revenue Next Year
$12.08
$11.62
P/E Ratio
★ N/A
$42.82
Revenue Growth
★ 3.66
N/A
52 Week Low
$17.72
$7.23
52 Week High
$44.28
$20.99

Technical Indicators

Market Signals
Indicator
CSTL
GILT
Relative Strength Index (RSI) 52.00 29.24
Support Level $33.90 $7.23
Resistance Level $37.42 $10.39
Average True Range (ATR) 1.76 0.31
MACD 0.23 0.02
Stochastic Oscillator 47.06 6.71

Price Performance

Historical Comparison
CSTL
GILT

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.

Share on Social Networks: